Organization
Samsung Bioepis Co., Ltd., Incheon, Korea, Republic Of
3 abstracts
Abstract
A RANDOMISED, DOUBLE-BLIND, PHASE III STUDY COMPARING SB2, AN INFLIXIMAB BIOSIMILAR, TO THE INFLIXIMAB REFERENCE PRODUCT (REMICADE®) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY Org: Daegu Catholic University Medical Center, Daegu, Korea, Republic Of, Clinical Center Banja Luka, Banja Luka, Bosnia and Herzegovina, Medica Pro Familia, Gdynia, Poland, MHAT “Dr. Ivan Seliminski”, AD, Sliven, Bulgaria, MEDICAL PLUS s.r.o, Uherske Hradiste, Czech Republic,
Abstract
A PHASE I PHARMACOKINETIC STUDY COMPARING SB4, AN ETANERCEPT BIOSIMILAR, AND ETANERCEPT REFERENCE PRODUCT (ENBREL®) IN HEALTHY MALE SUBJECTS Org: Samsung Bioepis Co., Ltd., Incheon, Korea, Republic Of, PAREXEL International Early Phase Clinical Unit, Berlin, Germany,
Abstract
A PHASE III RANDOMISED, DOUBLE-BLIND CLINICAL STUDY COMPARING SB4, AN ETANERCEPT BIOSIMILAR, WITH ETANERCEPT REFERENCE PRODUCT (ENBREL®) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY (24-WEEK RESULTS) Org: NZOZ Medica Pro Familia Sp. z o.o., Warsaw, Poznanski Osrodek Medyczny NOVAMED, Poznan, Poland, Medicome Sp. z o.o., Oswiecim, Poland, Samsung Bioepis Co., Ltd., Incheon, Korea, Republic Of,